Syros to Present New Data on Lead Drug Candidates, SY-1425 and SY-1365, and CDK12/13 Inhibitor Program at
Upcoming AACR Annual Meeting
Presentations Highlight Therapeutic Potential of Company’s Clinical and Preclinical Programs and Leadership
in Gene Control
Syros Pharmaceuticals (NASDAQ: SYRS), a biopharmaceutical company pioneering the development of medicines to control the
expression of disease-driving genes, today announced that the Company will present new data on three of its clinical and
preclinical programs at the American Association for Cancer Research (AACR) Annual Meeting taking place April 1-5 in Washington,
D.C.
The new data will be highlighted in five presentations:
- Three on SY-1425, an oral first-in-class selective retinoic acid receptor alpha (RARα) agonist that
is currently in a Phase 2 clinical trial in defined subsets of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS)
patients with a RARA biomarker;
- One on SY-1365, a first-in-class selective cyclin-dependent kinase 7 (CDK7) inhibitor that is on
track to begin a Phase 1 trial in the first half of this year in transcriptionally driven solid tumors; and
- One on its cyclin-dependent kinase 12/13 (CDK12/13) inhibitor program.
“The presentations at AACR showcase both the productivity of Syros’ gene control platform and the potential of our
first-in-class programs to provide a meaningful benefit for patients with a range of aggressive cancers both as single agents and
in combination with other targeted therapies,” said Nancy Simonian, M.D., Chief Executive Officer of Syros. “Our platform is the
first focused solely on the regulatory genome to systematically identify and target disease-causing alterations in gene expression
with the aim of treating diseases that have eluded other genomic-based approaches. In just three years since our inception, this
pioneering approach has led to a robust and growing pipeline, with our lead program in a Phase 2 clinical trial, our second program
poised to start clinical development in the first half of this year and multiple other programs in preclinical development. We are
excited to be presenting data from multiple programs across all stages of our pipeline.”
Details on the presentations are as follow:
Date & Time: Monday, April 3, from 8 a.m. - 12 p.m. ET
Presentation Title: AML patient clustering by super-enhancers reveals an RARA associated transcription factor signaling
partner
Session Category: Molecular and Cellular Biology / Genetics
Session Title: Targeting Aberrant Transcription in Cancer
Presenter: Michael R. McKeown, Ph.D., Senior Scientist, Translational Biology, Syros
Abstract Number: 1511
Location: Walter E. Washington Convention Center, Halls A-C, Poster Section 20
Date & Time: Monday, April 3, from 8 a.m. - 12 p.m. ET
Presentation Title: SY-1365, a potent and selective CDK7 inhibitor, exhibits promising anti-tumor activity in multiple preclinical
models of aggressive solid tumors
Session Category: Experimental and Molecular Therapeutics
Session Title: New Targets 1
Presenter: Christian Fritz, Ph.D., Vice President, Biology, Syros
Abstract Number: 1151
Location: Walter E. Washington Convention Center, Halls A-C, Poster Section 4
Date & Time: Monday, April 3, from 8 a.m. - 12 p.m. ET
Presentation Title: Targeting the transcriptional kinases CDK12 and CDK13 in breast and ovarian cancer
Session Category: Experimental and Molecular Therapeutics
Session Title: New Targets 1
Presenter: Michael Bradley, Ph.D., Principal Scientist, Biochemistry & Biophysics, Syros
Abstract Number: 1143
Location: Walter E. Washington Convention Center, Halls A-C, Poster Section 4
Date & Time: Monday, April 3, from 1 - 5 p.m. ET
Presentation Title: SY-1425, a selective RARα agonist, induces high levels of CD38 expression in RARA-high AML tumors creating a
susceptibility to anti-CD38 therapeutic antibody treatment
Session Category: Immunology
Session Title: Immune Response to Hematopoietic Tumors: New Development in Tumor Immunology
Presenter: Kathryn Austgen, Ph.D., Senior Scientist, Immuno-Oncology, Syros
Abstract Number: 2644
Location: Walter E. Washington Convention Center, Halls A-C, Poster Section 26
Date & Time: Tuesday, April 4, from 8 a.m. – 12 p.m. ET
Presentation Title: SY-1425 (tamibarotene), a selective RARα agonist, shows synergistic anti-tumor activity with hypomethylating
agents in a biomarker selected subset of AML
Session Category: Experimental and Molecular Therapeutics
Session Title: Differentiation Therapy
Presenter: Michael R. McKeown, Ph.D., Senior Scientist, Translational Biology, Syros
Abstract Number: 3085
Location: Walter E. Washington Convention Center, Halls A-C, Poster Section 3
About Syros Pharmaceuticals
Syros Pharmaceuticals is pioneering the understanding of the non-coding region of the genome to advance a new wave of medicines
that control expression of disease-driving genes. Syros has built a proprietary platform that is designed to systematically and
efficiently analyze this unexploited region of DNA in human disease tissue to identify and drug novel targets linked to genomically
defined patient populations. Because gene expression is fundamental to the function of all cells, Syros’ gene control platform
has broad potential to create medicines that achieve profound and durable benefit across a range of diseases. Syros is
currently focused on cancer and immune-mediated diseases and is advancing a growing pipeline of gene control medicines. Syros’ lead
drug candidates are SY-1425, a selective RARα agonist in a Phase 2 clinical trial for genomically defined subsets of patients with
acute myeloid leukemia and myelodysplastic syndrome, and SY-1365, a selective CDK7 inhibitor with potential in a range of solid
tumors and blood cancers. Led by a team with deep experience in drug discovery, development and commercialization, Syros is located
in Cambridge, Mass.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995,
including without limitation statements regarding the clinical progress of and potential benefits from treatment with SY-1425, the
initiation of clinical development of SY-1365, the ability to advance preclinical programs, and the benefits of Syros’ gene control
platform. The words ‘‘anticipate,’’ ‘‘believe,’’ ‘‘continue,’’ ‘‘could,’’ ‘‘estimate,’’ ‘‘expect,’’ ‘‘intend,’’ ‘‘may,’’ ‘‘plan,’’
‘‘potential,’’ ‘‘predict,’’ ‘‘project,’’ ‘‘target,’’ ‘‘should,’’ ‘‘would,’’ and similar expressions are intended to identify
forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results or events
could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of
various important factors, including: Syros’ ability to: advance the development of its programs, including SY-1425 and SY-1365,
under the timelines it projects ; obtain and maintain patent protection for its drug candidates and the freedom to operate under
third party intellectual property; demonstrate in any current and future clinical trials the requisite safety, efficacy and
combinability of its drug candidates; replicate scientific and non-clinical data in clinical trials; successfully develop a
companion diagnostic test to identify patients with biomarkers associated with the RARA super-enhancer; obtain and maintain
necessary regulatory approvals; identify, enter into and maintain collaboration agreements with third parties; manage competition;
manage expenses; raise the substantial additional capital needed to achieve its business objectives; attract and retain qualified
personnel; and successfully execute on its business strategies; risks described under the caption “Risk Factors” in the company’s
Quarterly Report on Form 10-Q for the quarter ended September 30, 2016, which is on file with the Securities and Exchange
Commission; and risks described in other filings that the company makes with the Securities and Exchange Commission in the future.
Any forward-looking statements contained in this press release speak only as of the date hereof, and Syros expressly disclaims any
obligation to update any forward-looking statements, whether because of new information, future events or otherwise.
![](http://cts.businesswire.com/ct/CT?id=bwnews&sty=20170301006330r1&sid=mstr1&distro=nx&lang=en)
Media Contact:
Syros Pharmaceuticals, Inc.
Naomi Aoki, 617-283-4298
naoki@syros.com
or
Investor Contact:
Stern Investor Relations, Inc.
Hannah Deresiewicz, 212-362-1200
hannahd@sternir.com
View source version on businesswire.com: http://www.businesswire.com/news/home/20170301006330/en/